Open Access Open Access  Restricted Access Subscription or Fee Access

Computational Analysis of TNRC9 (TOX3) Gene Related to Breast Cancer

K. S. Ravi Teja, R Kowshik Aravilli, Jahnavi R, Sai Lakshmi G, Harshavardhani V, Alpana Joshi

Abstract


Breast cancer is a disease in which women are more prone than men. Breast cancer completely depends upon type of cells that are present and cells that turn normal cells to abnormal cells. Breast cancer starts in the breast or the breast cancer which can be caused by some other cancers that had present in the body. In the United States, these cancers will affect more than 40,000 women. Women are typically the ones who develop these types of cancer. This means that the cancer will disrupt other cells and spread throughout the body, among those cells. Among those genes TNRC9 (trinucleotide-repeat-containing 9) also called as TOX3 is a gene which can induce breast cancer. This gene is involved in cell proliferation, and migration. Our aim of the study is to the gene (TOX3) which can downregulate the BRCA1 gene and proliferate breast cancer. TOX3 gene contains SNPs that are connected to breast cancer. TOX3 expression is highly significant in luminal subtype cancers. So n the current study we have focused on the Gene interaction, protein linkage studies, protein structure, peptide Analysis using different algorithms etc. among all we identified that TOX3 is more expressive than BRCA1 gene. Few Insilico studies revealed that ovarian and breast cancer cells of TOX3 and BRCA1 genes are inversely correlated.


Full Text:

PDF

References


Shan J, DSouza SP, Bakhru S, Al-Azwani EK, Ascierto ML, Sastry KS, Bedri S, Kizhakayil D, Aigha II, Malek J, Al-Bozom I. TNRC9 Downregulates BRCA1 Expression and Promotes Breast Cancer AggressivenessTNRC9 Role in Breast Cancer. Cancer research. 2013 May 1; 73 (9): 2840–9.

Cardon LR, Abecasis GR. Using haplotype blocks to map human complex trait loci. TRENDS in Genetics. 2003 Mar 1; 19 (3): 135–40.

Gilbert PM, Mouw JK, Unger MA, Lakins JN, Gbegnon MK, Clemmer VB, Benezra M, Licht JD, Boudreau NJ, Tsai KK, Welm AL. HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. The Journal of clinical investigation. 2010 May 3; 120 (5): 1535–50.

Zavala VA, Serrano-Gomez SJ, Dutil J, Fejerman L. Genetic epidemiology of breast cancer in Latin America. Genes. 2019 Feb 18; 10 (2): 153.

Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer treatment reviews. 2012 Oct 1; 38 (6): 698–707.

Baia GS, Caballero OL, Ho JS, Zhao Q, Cohen T, Binder ZA, Salmasi V, Gallia GL, Quinones-Hinojosa A, Olivi A, Brem H. NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic ApproachesNY-ESO-1 Expression in Meningioma. Cancer immunology research. 2013 Nov 1; 1 (5): 296–302.

Strausberg RL, Simpson AJ, Old LJ, Riggins GJ. Oncogenomics and the development of new cancer therapies. Nature. 2004 May; 429 (6990): 469–74.

Loi S, Sotiriou C, Haibe-Kains B, Lallemand F, Conus NM, Piccart MJ, Speed TP, McArthur GA. Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. BMC medical genomics. 2009 Dec; 2 (1): 1–9.

Simon R. Bioinformatics in cancer therapeutics—hype or hope?. Nature Clinical Practice Oncology. 2005 May; 2 (5): 223–223.

Savelyeva L, Schwab M. Amplification of oncogenes revisited: from expression profiling to clinical application. Cancer letters. 2001 Jun 26; 167 (2): 115–23.

Ouzounis CA. The emergence of bioinformatics: historical perspective, quick overview and future trends. Bioinformatics in cancer and cancer therapy. 2009: 1–1.

Gudas JM, Nguyen H, Li T, Cowan KH. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer research. 1995 Oct 15; 55 (20): 4561–5.

Wiggins GA, Black MA, Dunbier A, Morley-Bunker AE, Pearson JF, Walker LC. Increased gene expression variability in BRCA1-associated and basal-like breast tumours. Breast cancer research and treatment. 2021 Sep; 189 (2): 363–75.

Saleem M, Ghazali MB, Wahab MA, Yusoff NM, Mahsin H, Seng CN, Khalid IA, Rahman MN, Yahaya BH. The BRCA1 and BRCA2 genes in early-onset breast cancer patients. Cancer Biology and Advances in Treatment. 2018: 1–2.

Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS. A census of amplified and overexpressed human cancer genes. Nature Reviews Cancer. 2010 Jan; 10 (1): 59–64.

Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis. 2000 Sep 1; 21 (9): 1761–5.

Jara L, Morales S, Mayo TD, Gonzalez–Hormazabal P, Carrasco V, Godoy R. Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations. Biological research. 2017;50.

Chen F, Zhou J, Xue Y, Yang S, Xiong M, Li Y, Liu Q. A single nucleotide polymorphism of the TNRC9 gene associated with breast cancer risk in Chinese Han women. Genet Mol Res. 2014 Jan 10; 13 (1): 182–7.


Refbacks

  • There are currently no refbacks.